Intuitive Surgical (NASDAQ:ISRG) Shares Down 0.4% – Time to Sell?

Intuitive Surgical, Inc. (NASDAQ:ISRG)’s share price fell 0.4% during mid-day trading on Friday . The stock traded as low as $598.03 and last traded at $604.06. 310,260 shares traded hands during trading, a decline of 82% from the average session volume of 1,683,221 shares. The stock had previously closed at $606.57.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of analyst reports. UBS Group boosted their target price on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Morgan Stanley raised Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $522.00 to $650.00 in a report on Monday, December 2nd. Royal Bank of Canada boosted their target price on Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. CICC Research initiated coverage on Intuitive Surgical in a research report on Monday, January 27th. They set a “neutral” rating and a $550.00 price target on the stock. Finally, Stifel Nicolaus increased their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Stock Down 2.4 %

The company has a market cap of $210.96 billion, a price-to-earnings ratio of 92.37, a P/E/G ratio of 5.87 and a beta of 1.39. The business has a fifty day simple moving average of $564.41 and a 200 day simple moving average of $523.46.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 408 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total value of $240,618.00. Following the sale, the executive vice president now owns 353 shares of the company’s stock, valued at $208,181.75. This represents a 53.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,967,734. This trade represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,348 shares of company stock valued at $3,587,582. Corporate insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Large investors have recently bought and sold shares of the stock. Atala Financial Inc acquired a new position in Intuitive Surgical in the 4th quarter valued at about $25,000. Hurley Capital LLC acquired a new position in Intuitive Surgical in the 4th quarter valued at $28,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth $26,000. Parvin Asset Management LLC purchased a new stake in shares of Intuitive Surgical in the fourth quarter valued at $26,000. Finally, BankPlus Trust Department acquired a new position in Intuitive Surgical in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.